Skip to main content

Advertisement

Table 3 Fasting laboratory parameters of ziprasidone and olanzapine-treated patients (n = 10 per group)

From: Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study

  Ziprasidone start Ziprasidone end   Olanzapine start Olanzapine end   Ziprasidone change (%)a Olanzapine change (%)a  
Measure Median (IQR) Median (IQR) Pb Median (IQR) Median (IQR) Pb Median (IQR) Median (IQR) Pc
Cholesterol (mg/dl) 153.50 (143.00, 175.00) 171.00 (154.00, 185.25) 0.021* 176.50 (154.40, 205.75) 200.00 (160.00, 223.50) 0.203 4.95 (1.99, 24.55) 15.39 (−7.49, 22.09) >0.99
Triglyceride (mg/dl) 89.00 (63.00, 112.75) 88.50 (81.00, 154.25) 0.114 73.50 (58.00, 106.50) 118.00 (71.50, 180.75) 0.086 30.35 (−3.72, 58.04) 62.54 (−3.08, 137.66) 0.290
HDL-C (mg/dl) 49.50 (44.00, 54.25) 58.50 (52.50, 61.50) 0.036* 59.00 (47.00, 65.25) 50.00 (46.75, 55.75) 0.092 7.36 (1.19, 29.55) −13.24 (−23.56 , -4.02) 0.008*
LDL-C (mg/dl) 85.00 (71.55, 104.95) 100.00 (81.50, 109.00) 0.144 106.00 (77.50, 115.00) 129.00 (116.50, 143.00) 0.043* 7.07 (−0.68, 19.31) 16.04 (3.76, 84.25) 0.347
Glucose (mg/dl) 90.50 (81.75, 95.50) 95.50 (86.75, 98.00) >0.99 89.50 (83.00, 96.50) 98.00 (87.75, 108.50) 0.241 −1.08 (−6.89, 6.69) 4.58 (−3.38, 17.92) 0.496
Insulin (IU/ml) 9.55 (5.58, 13.18) 6.30 (3.80, 10.35) 0.169 9.25 (5.85, 11.95) 6.75 (3.73, 10.50) 0.333 −25.46 (−47.37, 15.95) −27.35 (−59.38, 39.37) 0.705
C-peptide (ng/ml) 2.30 (1.15, 2.45) 1.95 (1.25, 2.25) 0.357 1.70 (1.65, 2.33) 2.15 (1.35, 3.23) 0.314 −11.01 (−14.13, 15.56) 8.06 (−18.20, 89.71) 0.273
Prolactin (ng/ml) 9.55 (5.58, 13.18) 7.35 (6.15, 43.30) 0.285 10.95 (7.18, 19.38) 19.10 (11.33, 28.10) 0.028* 31.40 (−45.21, 262.32) 28.06 (−8.06, 122.40) 0.880
  1. IQR Interquartile Range, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol.
  2. a, posttreatment baseline baseline * 100; b,Wilcoxon signed rank test; c, Kruskal-Wallis H test; *, p < 0.05.